Avelumab, Palbociclib and Axitinib in Advanced RCC
Condition(s):Advanced Clear Cell Renal Cell CarcinomaLast Updated:September 7, 2023Withdrawn
Hide Studies Not Open or Pending
Condition(s):Advanced Clear Cell Renal Cell CarcinomaLast Updated:September 7, 2023Withdrawn
Condition(s):Primary Tumor; Renal Cell CarcinomaLast Updated:January 9, 2017Terminated
Condition(s):Kidney CancerLast Updated:June 8, 2015Terminated
Condition(s):Carcinoma, Renal CellLast Updated:January 29, 2021Completed
Condition(s):Renal Cell Carcinoma; Hereditary Leiomyomatosis; Renal Cell CancerLast Updated:January 26, 2021Terminated
Condition(s):Renal Cell CarcinomaLast Updated:January 25, 2024Active, not recruiting
Condition(s):Carcinoma, Renal CellLast Updated:March 22, 2023Completed
Condition(s):Kidney CancerLast Updated:February 27, 2014Unknown status
Condition(s):Hepatocellular Carcinoma; Renal Cell CarcinomaLast Updated:May 6, 2022Terminated
Condition(s):Renal Cell CancerLast Updated:August 29, 2016Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.